Compare SEM & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEM | ARDX |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2009 | 2014 |
| Metric | SEM | ARDX |
|---|---|---|
| Price | $15.18 | $7.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $16.33 | $12.95 |
| AVG Volume (30 Days) | 561.1K | ★ 6.6M |
| Earning Date | 02-19-2026 | 02-19-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $5,368,760,000.00 | $398,234,000.00 |
| Revenue This Year | $5.53 | $22.65 |
| Revenue Next Year | $4.33 | $31.33 |
| P/E Ratio | $19.94 | ★ N/A |
| Revenue Growth | 45.29 | ★ 58.12 |
| 52 Week Low | $11.65 | $3.21 |
| 52 Week High | $20.83 | $8.40 |
| Indicator | SEM | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 52.75 | 64.36 |
| Support Level | $15.09 | $6.73 |
| Resistance Level | $15.48 | $8.40 |
| Average True Range (ATR) | 0.28 | 0.56 |
| MACD | -0.02 | 0.11 |
| Stochastic Oscillator | 56.34 | 80.31 |
Select Medical Holdings Corp is a healthcare company that operates through three segments: critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics. Critical illness recovery hospitals which derives maximum revenue consists of hospitals designed to serve the needs of patients recovering from critical illnesses, often with complex medical needs. The rehabilitation hospital segment consists of hospitals designed to serve patients that require intensive physical rehabilitation care. Patients are typically admitted to critical illness recovery hospitals and rehabilitation hospitals from general acute care hospitals. The outpatient rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.